SWP
MDGL icon

ShoreHaven Wealth Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

ShoreHaven Wealth Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-534
Closed -$62K – 171
2021
Q1 		$62K Hold
534
– – 0.03% 105
2020
Q4 		$59K Buy
+534
New +$65.3K 0.03% 98

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

ShoreHaven Wealth Partners's MDGL Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2021, closing a stake of 534 shares — an estimated $62K sold.

ShoreHaven Wealth Partners first reported a position in MDGL in Q4 2020 and held it in 2 quarters. The position peaked at $62K in Q1 2021. 151 funds tracked by Wall St. Rank hold MDGL as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 534 Madrigal Pharmaceuticals shares in Q2 2021, an estimated $62K.
  • ShoreHaven Wealth Partners first reported a position in Madrigal Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • ShoreHaven Wealth Partners's Madrigal Pharmaceuticals position peaked at $62K in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.